Claro Advisors LLC Invests $233,000 in AstraZeneca PLC (NASDAQ:AZN)

Claro Advisors LLC bought a new stake in AstraZeneca PLC (NASDAQ:AZN) during the 3rd quarter, HoldingsChannel.com reports. The firm bought 2,988 shares of the company’s stock, valued at approximately $233,000.

A number of other institutional investors have also recently made changes to their positions in AZN. McClarren Financial Advisors Inc. grew its stake in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares in the last quarter. GHP Investment Advisors Inc. purchased a new stake in shares of AstraZeneca in the second quarter valued at approximately $26,000. Capital Performance Advisors LLP purchased a new stake in shares of AstraZeneca in the third quarter valued at approximately $28,000. Pathway Financial Advisers LLC acquired a new stake in shares of AstraZeneca in the first quarter valued at approximately $29,000. Finally, Hobbs Group Advisors LLC purchased a new position in AstraZeneca during the second quarter worth approximately $35,000. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Trading Up 0.6 %

NASDAQ AZN opened at $63.80 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The stock has a market capitalization of $197.82 billion, a P/E ratio of 30.53, a PEG ratio of 1.17 and a beta of 0.47. The firm’s 50-day moving average is $74.34 and its two-hundred day moving average is $78.06. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period in the prior year, the business posted $0.87 EPS. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, sell-side analysts anticipate that AstraZeneca PLC will post 4.07 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AZN. TD Cowen raised their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.